RxDoctor Payments DataLook up a doctor →

Michael Sy, MD

Neurology · Irvine, CANPI 1376835629

Payments from drug & device makers

$1,782,059in general payments, 2019–2025

Across 327 payments — averaging $5449.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$944K
  • Novartis$216K
  • Sanofi$212K
  • TG Therapeutics, Inc.$207K
  • AstraZeneca$77K
  • E.r. Squibb & Sons, L.L.C.$47K
  • plus $79K from 8 others

What the payments were for

  • Consulting fees$37,36841%
  • Speaking & faculty fees$43,46048%
  • Travel & lodging$5,1346%
  • Food & beverage$4,9205%
  • Education$1190%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.99$944,342
Novartis37$215,895
Sanofi20$212,131
TG Therapeutics, Inc.40$206,897
AstraZeneca(2 entities)59$76,946
E.r. Squibb & Sons, L.L.C.4$46,602
Bristol Myers Squibb7$37,024
Genentech USA, Inc.17$13,795
Biogen11$12,644
Amgen(2 entities)17$6,066
AbbVie3$5,016
UCB, Inc.2$4,474
Vanda Pharmaceuticals Inc.10$209
Therapeuticsmd, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,782,059 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$44,051
Medicare patients
164
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab58$1,643,678
UltomirisRavulizumab-Cwvz12$782,850
EnspryngSatralizumab-Mwge43$736,556
Kesimpta PenOfatumumab56$460,190
CopaxoneGlatiramer Acetate53$383,657
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$225,262
TecfideraDimethyl Fumarate15$131,336
Glatiramer Acetate47$84,076
Dalfampridine ErDalfampridine26$19,013
Aimovig AutoinjectorErenumab-Aooe14$13,226
Baclofen103$4,072
Dimethyl Fumarate13$2,967
Lacosamide13$2,268
Gabapentin54$1,172
Duloxetine Hcl20$1,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris, Ultomiris$76,946$2,426,52870 claims
Genentech USA, Inc.Enspryng$13,795$736,55643 claims
BiogenTecfidera$12,644$131,33615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →